NEW YORK (GenomeWeb News) – The Translational Genomics Reserach Institute will play a "primary" role in a $10.7-million Department of Defense breast cancer research program, the nonprofit said yesterday.
The multi-institutional, five-year research program is led by Philadelphia’s Fox Chase Cancer Center. The grant focuses on developing a new treatment model for breast cancer to reverse resistance to anti-estrogen therapy.
TGen will collaborate with FCCC and Georgetown University to map the genetic and biological events associated with breast tumor cells and analyze the results to identify patterns consistent with resistance to various anti-hormone therapies.
A Johns Hopkins University team will evaluate the patterns under phase I and II clinical studies.
The ultimate goal of the study is to exploit the knowledge of measurable similarities shared by drug-resistant breast cancers and translate that knowledge into more accurate prognostic tests and pharmacogenomic treatments.